This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Dose-Limiting Toxicities (DLTs)
Timeframe: Day 0 to Day 28 post-infusion
Incidence of Adverse Events (AEs)
Timeframe: Up to 12 Months After UCAR T-cell Infusion
Clinical response of AIHA who have failed ≥ 3 lines of therapy
Timeframe: Up to 24 Weeks After UCAR T-cell Infusion